Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assists in connection with the acquisition of Alergovet S.L.
Mandate

Vinge assists in connection with the acquisition of Alergovet S.L.

December 14, 2016

Vinge assists Nextmune Holding B.V., primarily owned by Fidelio Capital and Premune, in connection with the acquisition of the shares in Alergovet S.L. Alergovet is a leading company in Southern Europe focused on the diagnoses and treatment of atopic dermatitis for companion animals and horses, and offers high quality allergy tests and allergen-specific immunotherapy treatment for companion animals and horses.

Vinge’s team consists of partner Jonas Johansson together with, among others, associates Albert Wållgren, Linn Adelwald, Isabell Nielsen, Andréa Nicolin, Gustav Tengblad and Sofia Bergenstråhle.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025